ACRS 3.96 (-13.73%)
US00461U1051BiotechnologyBiotechnology

Aclaris Therapeutics (ACRS) Financial Metrics

This table shows a selected set of financial data points of Aclaris Therapeutics (ACRS). You can choose which elements to display by selecting the desired chart and column.

MarketCap

Total Revenue

Free CashFlow

Year EPS Dividend Yield PE Ratio MarketCap Return On Assets Total Revenue Free CashFlow EBITDA Net Income Cash
2023 -1.27 0 -0.83 73.3M -0.39 31.25M -79.63M -134.41M -88.48M 39.88M
2022 -1.33 0 -11.82 1.03B -0.34 29.75M -68.17M -79.66M -86.91M 45.28M
2021 -1.6 0 -9.08 824.86M -0.56 6.76M -52.44M -40.12M -90.87M 27.35M
2020 -1.2 0 -5.4 275.23M -0.6 6.48M -39.09M -44.8M -51.02M 22.06M
2019 -3.9 0 -0.48 78.1M -0.86 4.23M -98.06M -74.05M -161.35M 35.94M
2018 -4.03 0 -1.83 243.2M -0.51 10.09M -102.17M -130.86M -132.74M 57.02M
2017 -2.44 0 -10.11 693M -0.33 1.68M -55.9M -69.95M -68.52M 20.2M
2016 -2.25 0 -12.09 581.22M -0.36 0 -34.84M -47.96M -48.08M 30.17M
2015 -3.37 0 -8 164.52M -0.37 0 -20.88M -20.47M -20.56M 9.85M
2014 -0.92 0 0 0 -0.54 0 -8.05M -8.51M -8.52M 10.76M
2013 -0.49 0 0 0 0 0 -4.92M -5.23M -5.24M 9.59M

Obligatory risk notice

We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.